Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Feedback PLC | MaxCyte | Primary Health Properties PLC

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.

Feedback PLC

RSS Portfolio


Getting the most out of every image

In an environment with ever more powerful computing possibilities, new drugs under development, and the constant need to evaluate the effectiveness of complex treatment choices, medical imaging is an integral and growing part of medical practice.

Feedback is at the forefront of medical image processing, analysis expertise and novel quantification techniques with our Cadran and Texrad product families.


. Medical imaging tools for decision support
. Cadran Image Storage Management offers fully featured image display, review and manipulation options and enterprise archiving for clinical, non-clinical and teaching use
. Medical images wherever and whenever you need them. Fully featured archive, robust and secure.

Cadran is produced by Cambridge Computed Imaging Ltd. CCI are specialists in providing software that helps doctors use medical images to make decisions.

Clinicians can display, review and manipulate images using in-line measurement and analysis tools to assist diagnosis and quantify treatment response.


. Stratification of clinical diagnostic images for prognosis, risk and treatment response
. TexRAD analyses the textures in radiological scans and has the potential to assist clinicians in assessing the prognosis of patients with cancer. TexRAD analysis has been retrospectively performed on images from a wide range of conditions including colorectal, breast, lung, prostrate, oesophageal, head and neck, and renal cancers
TexRAD offers an innovative quantitative tool to clinicians researching the diagnosis, prognosis and treatment response of cancer.

TexRAD helps users analyse, detect and measure textures in medical images, revealing more information than is evident to the naked eye.

Market: LSE
52-week High/Low: 3.500p / 0.902p
Market Cap: 3.42M

View full company profile


RSS Portfolio


We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.

This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.

We are developing CARMA, our proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges. To read more click here.


Market: AIM
52-week High/Low: 254.000p / 175.000p
Market Cap: 111.15M

View full company profile

Primary Health Properties PLC

RSS Portfolio


Primary Health Properties PLC (“PHP”) is a UK Real Estate Investment Trust (“REIT”) and the leading investor in modern primary healthcare premises.

The objective of the Group is to create progressive returns to shareholders through a combination of earnings growth and capital appreciation.

PHP achieves this by investing in healthcare real estate in the UK and Ireland let on long term leases backed by a secure underlying covenant funded mostly by government bodies.

Market: LSE
52-week High/Low: 133.400p / 106.400p
Market Cap: 1,436.09M

View full company profile

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use